Calamos Advisors
NBIX icon

Calamos Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Calamos Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,122
Closed -$567K – 983
2024
Q2 		$567K Sell
4,122
-2,651
-39% -$364K ﹤0.01% 699
2024
Q1 		$934K Buy
6,773
+338
+5% +$46.2K ﹤0.01% 649
2023
Q4 		$848K Buy
+6,435
New +$741K ﹤0.01% 682
2023
Q1 		– Sell
-13,879
Closed -$1.66M – 1188
2022
Q4 		$1.66M Buy
13,879
+6,492
+88% +$760K 0.01% 817
2022
Q3 		$785K Buy
+7,387
New +$750K ﹤0.01% 976
2019
Q4 		– Sell
-96,622
Closed -$8.71M – 801
2019
Q3 		$8.71M Sell
96,622
-125
-0.1% -$11.7K 0.05% 373
2019
Q2 		$8.17M Buy
+96,747
New +$7.94M 0.05% 384

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Calamos Advisors's NBIX Position: Q3 2024 in Review

Calamos Advisors sold out of Neurocrine Biosciences (NBIX) in Q3 2024, closing a stake of 4,122 shares — an estimated $567K sold.

Calamos Advisors first reported a position in NBIX in Q2 2019 and held it in 7 quarters. The position peaked at $8.71M in Q3 2019. 574 funds tracked by Wall St. Rank hold NBIX as of Q3 2024.

  • Calamos Advisors reported no remaining Neurocrine Biosciences position as of Q3 2024 after selling out during the quarter.
  • Calamos Advisors sold 4,122 Neurocrine Biosciences shares in Q3 2024, an estimated $567K.
  • Calamos Advisors first reported a position in Neurocrine Biosciences in Q2 2019 and held it in 7 quarters.
  • Calamos Advisors's Neurocrine Biosciences position peaked at $8.71M in Q3 2019.
  • 574 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2024.

Based on Calamos Advisors's 13F filing for Q3 2024, filed 7 Nov 2024.